| Project/Area Number |
16H06909
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
Suda Kenji 京都大学, 医学研究科, 医員 (70779157)
|
|---|
| Research Collaborator |
MURAKAMI Tatsuya 富山県立大学, 工学部医薬品工学科, 教授
|
|---|
| Project Period (FY) |
2016-08-26 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 点眼ドラッグデリバリーシステム / 高比重リポタンパク / 加齢黄斑変性 / 眼科学 / ドラッグデリバリーシステム / ナノ材料 / HDL（高比重リポタンパク） |
|---|
| Outline of Final Research Achievements |
We have developed the novel drug delivery system using mutated forms of recombinant high-density lipoprotein (HDL), which is famous for anti-atherogenic property. For the achievement of less-invasive therapy of age-related macular degeneration, we searched for anti-angiogenetic drug that can be encapsulated into recombinant HDL. As a result, we succeeded in preparation of a recombinant HDL mutant loaded with pazopanib hydrochloride. We also confirmed the therapeutic potential of the complex in laser-induced choroidal neovascularization model mice.
|
